Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
) CEO Lars Jorgensen has agreed to testify voluntarily in a September hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Senate panel to weigh Novo Nordisk subpoena on Ozempic, Wegovy pricesThe U.S. Senate health panel said on Tuesday it would vote this month on whether to subpoena Novo Nordisk to answer questions about U.S. prices for weight loss drugs Ozempic and Wegovy, which are far higher than those in other countries.
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulinsThe rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Read more »
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulinsThe rivalry between Eli Lilly and Novo Nordisk extends beyond weight loss and diabetes drugs. Meanwhile, Uber has announced new features for caregivers.
Read more »
Boeing CEO to testify in Senate hearing June 18Boeing's departing CEO Dave Calhoun will face lawmakers' questions about aircraft quality and whistleblower allegations.
Read more »
Boeing CEO to testify before U.S. Senate panel on June 18Boeing CEO to testify before U.S. Senate panel on June 18
Read more »
Io.net CEO Ahmad Shadid steps down from CEO role days before token launchThe decentralized infrastructure provider has faced questions from critics in recent months regarding the veracity of its reported metrics.
Read more »